KAHR medical

Indonesia
Sumbul, North Sumatra, Indonesia, 91120

Company profile

KAHR medical company profile

KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment options for cancer and autoimmune disorders.

Business identity

Contact email
[email protected]
Phone number
97246392752
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2005-01-01, Year

Headquarters

Postal code
91120
Country code
ID
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
14
Total equity funding
$128.9M
Last funding
Series B / $22M / 2025-10-15
Last equity funding
Series B / $22M
Investors
17
Lead investors
5
Articles
18

Founders and investors

Lead investors

aMoon FundFlerie InvestMyeloma Investment FundPeregrine VenturesSPRIM Global Investments

Investors

Korea Investment PartnersPavilion CapitalPeregrine VenturesSanofiSanofi Ventures